As such, even in MET-Driven tumors, PD-L1, as well as other inhibitory immune checkpoint molecules21,30 were upregulated in tumor cells, this immunosuppressive and exclusive TME would attenuate the efficacy of immunotherapy31. The gene discussed is CD274; the disease is neoplasm.